[1] “Hepatitis C.” [Online]. Available: https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c. [Accessed: 19-Apr-2020].
[2] World Health Organization, World Health Organization, and Replacement of (work) World Health Organization., Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. .
[3] J. V. Lazarus et al., “The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations,” Seminars in Liver Disease. 2018.
[4] M. Miedouge, K. Saune, N. Kamar, M. Rieu, L. Rostaing, and J. Izopet, “Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients,” J. Clin. Virol., vol. 48, no. 1, pp. 18–21, May 2010.
[5] S. Chevaliez, A. Soulier, L. Poiteau, M. Bouvier-Alias, and J. M. Pawlotsky, “Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C,” J. Clin. Virol., vol. 61, no. 1, pp. 145–148, 2014.
[6] C. A. Rongey, F. Kanwal, T. Hoang, A. L. Gifford, and S. M. Asch, “Viral RNA Testing in Hepatitis C Antibody-Positive Veterans,” Am. J. Prev. Med., vol. 36, no. 3, pp. 235–238, 2009.
[7] F. M. J. Lamoury et al., “Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse,” J. Clin. Virol., vol. 92, pp. 32–38, Jul. 2017.
[8] J. M. Freiman et al., “Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: A systematic review and meta-analysis,” Ann. Intern. Med., vol. 165, no. 5, pp. 345–355, Sep. 2016.
[9] I. Mederacke et al., “Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease,” Nephrol. Dial. Transplant., vol. 26, no. 8, pp. 2648–2656, 2011.
[10] I. Mederacke et al., “HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on haemodialysis,” J. Clin. Virol., vol. 53, no. 2, pp. 110–115, Feb. 2012.
[11] G. Li Cavoli et al., “Hepatitis C Virus Core Antigen Test in Monitoring of Dialysis Patients,” Hepat. Res. Treat., vol. 2012, pp. 1–4, 2012.
[12] P. Jülicher and C. Galli, “Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting,” J. Med. Econ., vol. 21, no. 1, pp. 1–10, 2018.
[13] R. Wasitthankasem et al., “HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: Implications for improved diagnostic option in an era of affordable DAAs,” PeerJ, vol. 2017, no. 11, 2017.
[14] A. Chakravarti, M. S. Chauhan, G. Dogra, and S. Banerjee, “Hepatitis C virus core antigen assay: Can we think beyond convention in resource limited settings?,” Brazilian J. Infect. Dis., vol. 17, no. 3, pp. 369–374, May 2013.
[15] R. Alonso, F. Pérez-García, P. López-Roa, L. Alcalá, P. Rodeño, and E. Bouza, “HCV core-antigen assay as an alternative to HCV RNA quantification: A correlation study for the assessment of HCV viremia,” Enferm. Infecc. Microbiol. Clin., vol. 36, no. 3, pp. 175–178, 2018.
[16] L. T. Nguyen et al., “Hepatitis C virus core mutations associated with false-negative serological results for genotype 3a core antigen,” J. Clin. Microbiol., vol. 53, no. 8, pp. 2697–2700, Aug. 2015.
[17] A. R. Garbuglia et al., “HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes,” BMC Infect. Dis., vol. 14, no. 1, Apr. 2014.
[18] J. E. Trevizoli et al., “Hepatitis C is less aggressive in haemodialysis patients than in nonuremic patients,” Clin. J. Am. Soc. Nephrol., 2008.
[19] A. Goel, D. S. Bhadauria, and R. Aggarwal, “Hepatitis C virus infection and chronic renal disease: A review,” Indian J. Gastroenterol., vol. 37, no. 6, pp. 492–503, 2018.
[20] C. Galli, P. Julicher, and M. Plebani, “HCV core antigen comes of age: A new opportunity for the diagnosis of hepatitis C virus infection,” Clin. Chem. Lab. Med., vol. 56, no. 6, pp. 880–888, 2018.
[21] H. L. Tillmann, “Hepatitis C virus core antigen testing: Role in diagnosis, disease monitoring and treatment,” World J. Gastroenterol., 2014.
[22] E. Hadziyannis, M. Minopetrou, A. Georgiou, F. Spanou, and J. Koskinas, “Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay,” Ann. Gastroenterol., 2013.
[23] H. S. Wong and B. L. Goh, “24th Report of the Malaysian Dialysis & Transplant 2016,” 2018.
[24] F. Rahman et al., “AT THE EDGE OF A MIRACLE THE HEPATITIS C VIRUS (HCV) EPIDEMIC IN MALAYSIA,”. Malaysian AIDS Council: Kuala Lumpur, 2017
[25] S. Jasuja et al., “Prevalence and associations of hepatitis C viremia in haemodialysis patients at a tertiary care hospital,” Indian J. Nephrol., 2009.
[26] B. B. Patoli, A. A. Patoli, N. K. Balani, and A. A. Korejo, “Molecular surveillance of HCV mono-infection and HCV-HBV co-infection in symptomatic population at Hyderabad, Pakistan,” Afr. Health Sci., 2018.
[27] E. Umumararungu, F. Ntaganda, J. Kagira, and N. Maina, “Prevalence of Hepatitis C Virus Infection and Its Risk Factors among Patients Attending Rwanda Military Hospital, Rwanda,” Biomed Res. Int., 2017.
[28] J. Umutesi et al., “Screening a nation for hepatitis C virus elimination: A cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population,” BMJ Open, 2019.